Table 1.
Demographic, clinical, serological and virological characteristics of the 317 patients infected with HCV.
Table 2.
Clinical course of the 317 patients after liver biposy.
Fig 1.
Box-and-whisker plot of the serum Fuc-Hpt (A) and Mac-2 bp (B) levels for each liver fibrosis stage.
The top and bottom of each box represent the first and third quartiles, respectively, with the height of the box representing the interquartile range, covering 50% of the values. The line across each box represents the median. The error bars show the minimum and maximum values. The statistical analysis was performed with the Wilcoxon rank sum test. * P < 0.05. ** P < 0.001.
Fig 2.
The diagnostic abilities of the serum Fuc-Hpt and Mac-2 bp levels for assessing the stage of liver fibrosis.
The ROC curves and AUROC values of serum Fuc-Hpt and Mac-2 bp in F ≥ 2, F ≥ 3 and F4 stage liver fibrosis were shown in the figure.
Table 3.
The diagnostic abilities of each liver fibrosis marker for assessing the stage of liver fibrosis.
Table 4.
Factors associated with moderate liver fibrosis (F ≥ 2).
Table 5.
Factors associated with advanced liver fibrosis (F ≥ 3).
Table 6.
Factors associated with liver cirrhosis (F4).
Table 7.
The correlation coefficients between each of the liver fibrosis markers.
Table 8.
The diagnostic abilities of combinations with these glycoproteins.
Fig 3.
The cumulative hepatocellular carcinoma incidence rate.
The median follow-up period after liver biopsy was 2.4 years (Interquartile range; 1.0–4.9 years). HCC was detected in 19 patients during the follow-up period. The incidence rates at 1, 3 and 5 years in all patients were 1.8%, 4.3% and 9.2%, respectively, using the Kaplan-Meier method. (A) We divided these findings into two groups by the liver histology grade, F0-1 and F2-4, and the median (B) Fuc-Hpt (C) and Mac-2 bp (D) levels. These analysis were performed using the log-rank test.